<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930735</url>
  </required_header>
  <id_info>
    <org_study_id>09/0904</org_study_id>
    <nct_id>NCT00930735</nct_id>
  </id_info>
  <brief_title>The Prognostic Significance of Fibrosis Detection in Cardiomyopathy</brief_title>
  <official_title>The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems
      and lead to the developement of heart failure

      Clinical significance Correlation with biomarkers and genetic markers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left
      ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where
      appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion
      using pharmacological stress imaging (contraindications to include comorbidities that do not
      permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic
      stenosis)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular arrhythmias</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unplanned heart failure admissions</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA status</measure>
    <time_frame>3</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Myocardial fibrosis, outcomes</arm_group_label>
    <description>Groups with none and variable amounts of myocardial fibrosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma and myocardium
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive referrals for CMR from tertiary and nontertiary referral hospitals scanned to
        evaluate presence and amount of myocardial scarring.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of an ischaemic or non-ischaemic cardiomyopathic process

          -  no contraindication to contrast enhanced CMR

          -  GFR &gt;30

        Exclusion Criteria:

          -  ESRF

          -  Contraindication to CM R
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay K Prasad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton and Harefield Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjay K Prasad, MD</last_name>
    <phone>+442073528121</phone>
    <email>s.prasad@rbht.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Halliday, MD</last_name>
    <phone>+442073528121</phone>
    <phone_ext>8812</phone_ext>
    <email>b.halliday@rbht.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay K Prasad, MD</last_name>
      <phone>+442073518800</phone>
      <email>S.Prasad@rbht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rory R O' Hanlon, MD</last_name>
      <phone>+442073518800</phone>
      <email>R.O'Hanlon@rbht.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjay K Prasad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Sanjay Prasad</investigator_full_name>
    <investigator_title>Consultant Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

